Efficacy of antiparkinsonian therapy in tremor correction according to tremorography
https://doi.org/10.14412/2074-2711-2024-2-34-40
Abstract
Objective: to evaluate the efficacy of antiparkinsonian drugs of different groups considering the frequency-amplitude characteristics in the correction of tremulous hyperkinesis in Parkinson's disease (PD) using tremorography.
Material and methods. 172 patients with a confirmed diagnosis of PD were observed. Taking into account age and contraindications, patients were divided into four groups receiving one of four drugs in monotherapy: dopamine receptor agonists (ADR; pramipexole), levodopa (Tidomet forte), anticholinergics (biperiden), amantadines (amantadine sulfate). Before starting treatment and after completion of the selected therapy, patients underwent tremorography to analyse the frequency, amplitude and duration of tremor over time in four standard tests.
Results. All antiparkinsonian drugs reduced rest tremor, and the efficacy of pramipexole in treating tremor was comparable to that of levodopa in the early stages of the disease. As the severity of the disease increased, the efficacy of ADRs decreased, whereas levodopa became more important. Amantadine sulfate showed the lowest efficacy in rest tremor. The efficacy of anticholinergics against tremor is high but inconsistent.
Conclusion. We demonstrated feasibility of using tremorography in the selection of an individualised treatment programme for patients with shaking hyperkinesis in PD , and the high efficacy of levodopa in shaking hyperkinesis was confirmed.
About the Authors
V. A. Bogacheva
V.M. Bekhterev National Research Medical Center for Psychiatry and Neurology, Ministry of Health of Russia
Russian Federation
Competing Interests:
Russian Federation
3, Bekhtereva St., St. Petersburg 192019
Competing Interests:
This article has been supported by TORRENT PHARMACEUTICALS LTD. The conflict of interest has not affected the results of the investigation. The authors are solely responsible for submitting the final version of the manuscript for publication. All the authors have participated in developing the concept of the article and in writing the manuscript. The final version of the manuscript has been approved by all the authors.
D. V. Zakharov
V.M. Bekhterev National Research Medical Center for Psychiatry and Neurology, Ministry of Health of Russia
Russian Federation
Competing Interests:
Russian Federation
3, Bekhtereva St., St. Petersburg 192019
Competing Interests:
This article has been supported by TORRENT PHARMACEUTICALS LTD. The conflict of interest has not affected the results of the investigation. The authors are solely responsible for submitting the final version of the manuscript for publication. All the authors have participated in developing the concept of the article and in writing the manuscript. The final version of the manuscript has been approved by all the authors.
V. A. Mikhailov
V.M. Bekhterev National Research Medical Center for Psychiatry and Neurology, Ministry of Health of Russia
Russian Federation
Competing Interests:
Russian Federation
3, Bekhtereva St., St. Petersburg 192019
Competing Interests:
This article has been supported by TORRENT PHARMACEUTICALS LTD. The conflict of interest has not affected the results of the investigation. The authors are solely responsible for submitting the final version of the manuscript for publication. All the authors have participated in developing the concept of the article and in writing the manuscript. The final version of the manuscript has been approved by all the authors.
References
1. Litvinenko IV. Odinak MM. Rational approach to drug therapy is the basis for life quality management in patients with Parkinson's disease. Voyenno-meditsinskiy zhurnal. 2004;325(4):47-53 (In Russ.).
2. Gusev EI, Konovalov AN, Skvortsova VI, Gekht AB. Nevrologiya: Natsionalnoye rukovodstvo [Neurology: National Guide]. Moscow: GEOTAR-Media; 2009. 1035 p. (In Russ.).
3. Armstrong MJ, Okun MS. Diagnosis and Treatment of Parkinson Disease: A Review. JAMA. 2020 Feb 11;323(6):548-60. doi: 10.1001/jama.2019.22360
4. Madelein van der Stouwe AM, Nieuwhof F, Helmich RC. Tremor pathophysiology: lessons from neuroimaging. Curr Opin Neurol. 2020 Aug;33(4):474-81. doi: 10.1097/WCO.0000000000000829
5. Timmer J, Lauk M, Vach W, et al. A test for a difference between spectral peak frequencies. Comp Stat Data Anal. 1999;30:45-55.
6. Raethjen J, Govindan RB, Muthuraman M, et al. Cortical correlates of the basic and first harmonic frequency of Parkinsonian tremor. Clin Neurophysiol. 2009 Oct;120(10):1866-72. doi: 10.1016/j.clinph.2009.06.028. Epub 2009 Sep 12.
7. Pollok B, Makhloufi H, Butz M, et al. Levodopa affects functional brain networks in Parkinsonian resting tremor. Mov Disord. 2009 Jan 15;24(1):91-8. doi: 10.1002/mds.22318
8. Dirkx MF, Bologna M. The pathophysiology of Parkinson's disease tremor. J Neurol Sci. 2022 Apr 15;435:120196. doi: 10.1016/j.jns.2022.120196. Epub 2022 Feb 19.
9. Golubev VL. Diagnosis and treatment of the shaking form of Parkinson's disease. In: Illarioshkin SN, Yakhno NN, editors. Bolezn Parkinsona i rasstroystva dvizheniy [Parkinson's disease and movement disorders.]. Moscow: Dialog; 2008. P. 85-8 (In Russ.).
10. Yaw TK, Fox SH, Lang AE. Clozapine in Parkinsonian Rest Tremor: A Review of Outcomes, Adverse Reactions, and Possible Mechanisms of Action. Mov Disord Clin Pract. 2015 Dec 30;3(2):116-24. doi: 10.1002/mdc3.12266
11. Nodel M.R. Diagnostic criteria for Parkinson's disease. Rossiyskiy zhurnal geriatricheskoy meditsiny = Russian Journal of Geriatric Medicine. 2021;(1):92-6. doi: 10.37586/2686-8636-1-2021-92-96 (In Russ.).
12. Patient management protocol. Parkinson's disease (G20) [approved by the Ministry of Health and Social Development of the Russian Federation on January 14, 2005]. Problemy standartizatsii v zdravookhranenii. 2005;(3):74-166 (In Russ.).
13. Berardelli A, Wenning GK, Antonini A, et al. EFNS/MDS-ES/ENS [corrected] recommendations for the diagnosis of Parkinson's disease. Eur J Neurol. 2013 Jan;20(1):16-34. doi: 10.1111/ene.12022. Erratum in: Eur J Neurol. 2013 Feb;20(2):406.
14. Fedorova NV. Shtok VN. Strategy and tactics for treating Parkinson's disease. Konsilium. 2001;(5):237-42 (In Russ.).
15. Preobrazhenskaya IS, Yakhno NN. Treatment of Parkinson's disease. Consilium Medicum. 2002;4(2):85-91 (In Russ.).
16. Karaban IN et al. Parkinson's disease (G20): Clinical guidelines. Novosti meditsiny i farmatsii: Psikhiatriya i nevrologiya. 2007;215. Available at: http://www.mif-ua.com/archive/article/1396 (accessed 19.02.2014) (In Russ).
17. Levin OS. Standards of treatment for Parkinson's disease. Lechashchiy vrach. 2007;8/9. Available at: http://www.lvrach.ru/2007/08/4716383/ (accessed 20.06.2015) (In Russ.).
18. Levin OS, Datiyeva VK. Tremor in Parkinson's disease: features of phenomenology and treatment. Sovremennaya terapiya v psikhiatrii i nevrologii. 2014;(3):14-9 (In Russ.).
19. Golubev VL. Treatment algorithm for early stages of Parkinson's disease. Atmosfera: Nervnyye bolezni: Nevrologicheskiy algoritm. 2005;(4):9-12 (In Russ.).
20. Golubev VL. Treatment of Parkinson's disease: resolved and unresolved issues. In: Izbrannyye lektsii po nevrologii [Selected lectures on neurology]. Moscow: Eydos Media; 2006. P. 395-420 (In Russ.).
21. Ghosh TK. Early Parkinson’s Disease Tremor Characteristics: Identification & Treatment. J Psychiatry Neurochem Res. 2023. Epub 04 Sep 2023.
22. Jankovic J, Tan EK. Parkinson's disease: etiopathogenesis and treatment. J Neurol Neurosurg Psychiatry. 2020 Aug;91(8):795-808. doi: 10.1136/jnnp-2019-322338. Epub 2020 Jun 23.
23. Beckers M, Bloem BR, Verbeek MM. Mechanisms of peripheral levodopa resistance in Parkinson's disease. NPJ Parkinsons Dis. 2022 May 11;8(1):56. doi: 10.1038/s41531-022-00321-y
24. Zach H, Dirkx MF, Roth D, et al. Dopamine-responsive and dopamine-resistant resting tremor in Parkinson disease. Neurology. 2020 Sep 15;95(11):e1461-e1470. doi: 10.1212/WNL.0000000000010316. Epub 2020 Jul 10.
25. Smolentseva IG. Non-motor fluctuations in Parkinson's disease. In: Illarioshkin SN, Yakhno NN, editors. Bolezn Parkinsona i rasstroystva dvizheniy [Parkinson's disease and movement disorders]. Moscow: Dialog; 2008. P. 108-11 (In Russ.).
26. Lenka A, Jankovic J. Tremor Syndromes: An Updated Review. Front Neurol. 2021 Jul 26;12:684835. doi: 10.3389/fneur.2021.684835
27. De Bie RMA, Clarke CE, Espay AJ, et al. Initiation of pharmacological therapy in Parkinson's disease: when, why, and how. Lancet Neurol. 2020 May;19(5):452-61. doi: 10.1016/S1474-4422(20)30036-3. Epub 2020 Mar 12.
28. Рarkinson Study Group. A randomized controlled trial comparing pramipexole with levodopa in early Parkinson's disease: design and methods of the CALM-PD Study. Clin Neuropharmacol. 2000 Jan-Feb;23(1):34-44. doi: 10.1097/00002826-200001000-00007
29. Pringsheim T, Day GS, Smith DB, et al; Guideline Subcommittee of the AAN. Dopaminergic Therapy for Motor Symptoms in Early Parkinson Disease Practice Guideline Summary: A Report of the AAN Guideline Subcommittee. Neurology. 2021 Nov 16;97(20):942-57. doi: 10.1212/WNL.0000000000012868
30. Pogarell O, Gasser T, van Hilten JJ, et al. Pramipexole in patients with Parkinson's disease and marked drug resistant tremor: a randomised, double blind, placebo controlled multicentre study. J Neurol Neurosurg Psychiatry. 2002 Jun;72(6):713-20. doi: 10.1136/jnnp.72.6.713
31. Elble RJ. Tremor and dopamine agonists. Neurology. 2002 Feb 26;58(4 Suppl 1):S57-62. doi: 10.1212/wnl.58.suppl_1.s57
32. Karpova EA, Ivanova-Smolenskaya IA, Illarioshkin SN, et al. Dynamics of the main symptoms of Parkinson’s disease during pronoran therapy. Nevrologicheskiy zhurnal. 2003;8(2):49-52 (In Russ.).
33. Levin OS. Dopamine receptor agonists in the treatment of Parkinson's disease. Lecheniye nervnykh bolezney. 2003;4.1(9):14-7 (In Russ.).
34. Shavlovskaya OA. Quality of life of patients with Parkinson's disease during therapy with dopamine receptor agonists. Remedium: Zhurnal o rossiyskom rynke lekarstv i meditsinskoy tekhniki. 2014;(4):25-8 (In Russ.).
35. Amirdjanova VN, Goryachev DV, Korshunov NI, et al. SF-36 questionnaire population quality of life indices Objective. Nauchno-prakticheskaya revmatologiya = Rheumatology Science and Practice. 2008;46(1):36-48. doi: 10.14412/1995-4484-2008-852 (In Russ.).
Review
For citations:
Bogacheva VA, Zakharov DV, Mikhailov VA. Efficacy of antiparkinsonian therapy in tremor correction according to tremorography. Nevrologiya, neiropsikhiatriya, psikhosomatika = Neurology, Neuropsychiatry, Psychosomatics. 2024;16(2):34-40. (In Russ.) https://doi.org/10.14412/2074-2711-2024-2-34-40
Views:
323
Email this article 